Dualyx
About
VIB-linked biotech developing Treg-based immune modulators for hard-to-treat autoimmune diseases. Lead program DT-001 is a TNFR2 antibody agonist in IND-enabling studies. Founded 2020; raised EUR 40M Series A in 2023.
Know Dualyx?
We list a record's team, investors, portfolio and events once we can verify them. Send us what you know and we'll check it.
Suggest an edit